Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by PET/CT
Recruitment status was Recruiting
Patients affected with non-Hodgkin’s large B-cell lymphoma are treated by chemotherapy. The evaluation of the response to this treatment is made by Positron Emission Tomography (PET/CT) in many centres where this technology is available. Presently PET scans and CT scans are being performed before treatment, after 4 cycles of chemotherapy and a few months after the end of treatment.
The goal of this study is to determine if it is possible to evaluate the efficiency of chemotherapy treatments after one cycle of treatment instead of waiting after 4 cycles, using a new scanner that combines PET and CT modalities. Data available from studies on these combined exams suggest that PET/CT helps to rapidly evaluate the response of the chemotherapy treatment. We also want to verify if some pathological characteristics measured from tumor cells will enable doctors to predict in advance the response to treatment.
Procedure: PET/CT 20 days after the first cycle of chemotherapy
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by Positron Emission Tomography Coupled With Computed Tomography (PET/CT)|
- Disease free survival at 2 years
|Study Start Date:||November 2005|
|Estimated Study Completion Date:||November 2009|
Participation in this study involves 4 PET/CT exams, which occur before the treatments start, after the first cycle of chemotherapy, after 4 cycles of chemotherapy and then 12 weeks after the end of the treatments. The only additional test performed in this study compared to the regular follow-up of patients that are not in this study is the PET/CT exam after the first cycle. Your participation in this study will not affect treatment since the results of the first PET/CT test will not be communicated. All other tests results will be available in the medical record.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00256490
|Contact: Eric Turcotte, MD, FRCPC||819-346-1110 ext email@example.com|
|Contact: Chantal Langevin, inf||819-346-1110 ext firstname.lastname@example.org|
|Centre Hospitalier Universitaire de Sherbrooke||Recruiting|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Contact: Eric Turcotte, MD, FRCPC 819-346-1110 ext 11887 email@example.com|
|Principal Investigator:||Eric Turcotte, MD, FRCPC||Centre Hospitalier Universitaire de Sherbrooke|
|Principal Investigator:||Francois Bénard, MD, FRCPC||Centre Hospitalier Universitaire de Sherbrooke|
|Principal Investigator:||Virginie Bruneau, MD||Centre Hospitalier Universitaire de Sherbrooke|